The CAPItello-291 Trial: Final Overall Survival Results of Capivasertib and Fulvestrant in HR+/HER2− Advanced Breast Cancer - Report from ESMO BC 2026

Professor Hope S. Rugo discusses the final overall survival results from the Phase 3 CAPItello-291 trial, evaluating the efficacy, long-term disease control, and safety of combining the AKT inhibitor capivasertib with fulvestrant for patients with AI-resistant, HR+/HER2− advanced breast cancer.

Video: https://medicaldigest.org/scientific-contents/interview:capitello-291-trial-final-overall-survival-results-capivasertib-and-fulvestrant-hrher2-advanced-breast-cancer